Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma

Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma

Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced lung cancer is diagnosed in 41% of patients. Median overall survival in stage IV patients receiving chemotherapy is 7–12 months. Treatment for...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, P. N. Meshcheryakov, S. V. Oskin, S. N. Kabanov, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Format: Article
Language:Russian
Published: ANO "Perspective of oncology" 2021-03-01
Series:Южно-Российский онкологический журнал
Subjects:
non-small cell lung cancer
adenocarcinoma
pemetrexed
maintenance therapy
adverse effects
disease stabilization
Online Access:https://www.cancersp.com/jour/article/view/105
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.cancersp.com/jour/article/view/105

Similar Items